CA2557151A1 - Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite - Google Patents
Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite Download PDFInfo
- Publication number
- CA2557151A1 CA2557151A1 CA002557151A CA2557151A CA2557151A1 CA 2557151 A1 CA2557151 A1 CA 2557151A1 CA 002557151 A CA002557151 A CA 002557151A CA 2557151 A CA2557151 A CA 2557151A CA 2557151 A1 CA2557151 A1 CA 2557151A1
- Authority
- CA
- Canada
- Prior art keywords
- gip
- insulin
- glucose
- peptide analogue
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0404124.0 | 2004-02-25 | ||
GBGB0404124.0A GB0404124D0 (en) | 2004-02-25 | 2004-02-25 | Antagonists of GIP |
PCT/GB2005/000710 WO2005082928A2 (fr) | 2004-02-25 | 2005-02-25 | Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2557151A1 true CA2557151A1 (fr) | 2005-09-09 |
CA2557151C CA2557151C (fr) | 2015-02-17 |
Family
ID=32050802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2557151A Active CA2557151C (fr) | 2004-02-25 | 2005-02-25 | Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1730188A2 (fr) |
JP (1) | JP2008500280A (fr) |
AU (1) | AU2005217198A1 (fr) |
CA (1) | CA2557151C (fr) |
GB (1) | GB0404124D0 (fr) |
WO (1) | WO2005082928A2 (fr) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1809335A2 (fr) | 2004-10-25 | 2007-07-25 | Cytos Biotechnology AG | Systemes d'antigenes de polypeptides inhibiteurs gastriques et utilisations |
EP1943274A2 (fr) * | 2005-09-08 | 2008-07-16 | Uutech Limited | Traitement de l'obesite associee aux diabetes |
AU2006289259A1 (en) * | 2005-09-08 | 2007-03-15 | Uutech Limited | Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function |
WO2007056362A2 (fr) | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees |
EP2057188B1 (fr) * | 2006-08-17 | 2013-07-31 | Amylin Pharmaceuticals, LLC | Analogue du gip et polypeptides hybrides possédant des propriétés sélectives |
EP2124974B1 (fr) | 2007-01-05 | 2017-03-15 | Indiana University Research and Technology Corporation | Analogues de glucagon présentant une solubilité améliorée dans des tampons à ph physiologiques |
EP2111414B1 (fr) | 2007-02-15 | 2014-07-02 | Indiana University Research and Technology Corporation | Co-agonistes des récepteurs du glucagon/glp-1 |
GB0717388D0 (en) * | 2007-09-07 | 2007-10-17 | Uutech Ltd | Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission |
WO2009058734A1 (fr) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Composés présentant une activité d'antagoniste de glucagon et d'agoniste du glp-1 |
ES2509883T3 (es) | 2007-10-30 | 2014-10-20 | Indiana University Research And Technology Corporation | Antagonistas de glucagón |
WO2009067268A1 (fr) * | 2007-11-23 | 2009-05-28 | Michael Rothkopf | Procédés d'amplification de la résolution d'un diabète |
EA019203B9 (ru) | 2008-06-17 | 2014-03-31 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Коагонисты глюкагонового рецептора/glp-1-рецептора |
KR20110039230A (ko) | 2008-06-17 | 2011-04-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 생리학적 pH 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체 |
US9062124B2 (en) | 2008-06-17 | 2015-06-23 | Indiana University Research And Technology Corporation | GIP-based mixed agonists for treatment of metabolic disorders and obesity |
GB0814068D0 (en) * | 2008-08-01 | 2008-09-10 | Univ Ulster | Active immunisation against GIP |
EA020005B1 (ru) * | 2008-08-07 | 2014-07-30 | Ипсен Фарма С.А.С. | Аналоги глюкозазависимого инсулинотропного полипептида |
AU2009280017B2 (en) | 2008-08-07 | 2013-01-10 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide |
EP2915538A3 (fr) * | 2008-08-07 | 2015-10-14 | Ipsen Pharma S.A.S. | Analogues tronqués de polypeptide insulinotrope glucose-dépendant |
KR101593158B1 (ko) | 2008-08-07 | 2016-02-12 | 입센 파마 에스.에이.에스. | N-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(gip)의 유사체 |
TWI489992B (zh) | 2008-12-19 | 2015-07-01 | 印地安那大學研究及技術公司 | 醯胺系胰高血糖素超級家族之胜肽前驅藥物 |
JP5576694B2 (ja) * | 2009-04-10 | 2014-08-20 | 花王株式会社 | Gip上昇抑制剤 |
MX2011013625A (es) | 2009-06-16 | 2012-01-20 | Univ Indiana Res & Tech Corp | Compuestos glucagon activo de receptor de gip. |
EP2512503A4 (fr) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | Co-agonistes du récepteur du glucagon/glp-i |
MX2012008603A (es) | 2010-01-27 | 2013-01-25 | Univ Indiana Res & Tech Corp | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. |
EP2568993A4 (fr) | 2010-05-13 | 2014-02-19 | Univ Indiana Res & Tech Corp | Peptides de la superfamille du glucagon manifestant une activité de récepteur couplé à une protéine g |
ES2661228T3 (es) | 2010-05-13 | 2018-03-28 | Indiana University Research And Technology Corporation | Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona |
US9023986B2 (en) * | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
PE20140186A1 (es) | 2010-12-22 | 2014-02-13 | Univ Indiana Res & Tech Corp | Analogos de glucagon que presentan actividad de receptor de gip |
JP5914641B2 (ja) * | 2011-06-10 | 2016-05-11 | ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドBeijing Hanmi Pharmaceutical Co., Ltd. | グルコース依存性インスリン分泌刺激ポリペプチドのアナログ、医薬組成物及びその使用 |
GEP20176629B (en) | 2011-06-22 | 2017-02-27 | Indiana Unversity Research And Tech Corporation | Glucagon/glp-1 receptor co-agonists |
MX2013015168A (es) | 2011-06-22 | 2014-03-31 | Univ Indiana Res & Tech Corp | Co-agonista del receptor de glucagon/glp-1. |
KR20140097151A (ko) | 2011-11-17 | 2014-08-06 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드 |
JP6311708B2 (ja) | 2012-06-21 | 2018-04-18 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Gip受容体活性を示すグルカゴンアナローグ |
EP3985016A1 (fr) | 2014-10-29 | 2022-04-20 | Zealand Pharma A/S | Composés agonistes de gip et procédés associés |
JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
ES2972848T3 (es) | 2017-05-31 | 2024-06-17 | The Univ Of Copenhagen | Análogos de péptido GIP de acción prolongada |
TWI770085B (zh) * | 2017-11-21 | 2022-07-11 | 日商武田藥品工業股份有限公司 | 胜肽化合物 |
EP3788063B1 (fr) * | 2018-05-04 | 2023-08-09 | Novo Nordisk A/S | Dérivés de gip et leurs utilisations |
CN113827706B (zh) * | 2021-09-27 | 2023-12-26 | 南通大学 | Gip及其衍生肽作为制备皮肤创伤治疗药物中的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000058360A2 (fr) * | 1999-03-29 | 2000-10-05 | Uutech Limited | Peptide |
-
2004
- 2004-02-25 GB GBGB0404124.0A patent/GB0404124D0/en not_active Ceased
-
2005
- 2005-02-25 WO PCT/GB2005/000710 patent/WO2005082928A2/fr active Application Filing
- 2005-02-25 JP JP2007500292A patent/JP2008500280A/ja active Pending
- 2005-02-25 CA CA2557151A patent/CA2557151C/fr active Active
- 2005-02-25 EP EP05717793A patent/EP1730188A2/fr not_active Withdrawn
- 2005-02-25 AU AU2005217198A patent/AU2005217198A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2005082928A2 (fr) | 2005-09-09 |
JP2008500280A (ja) | 2008-01-10 |
CA2557151C (fr) | 2015-02-17 |
EP1730188A2 (fr) | 2006-12-13 |
WO2005082928A3 (fr) | 2005-12-01 |
GB0404124D0 (en) | 2004-03-31 |
AU2005217198A1 (en) | 2005-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2557151C (fr) | Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite | |
US7875587B2 (en) | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity | |
US6921748B1 (en) | Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes | |
KR102622642B1 (ko) | 인크레틴 유사체 및 그의 용도 | |
JP7211712B2 (ja) | グルカゴン受容体アゴニスト | |
KR101399178B1 (ko) | 선별가능한 특성을 갖는 하이브리드 폴리펩티드 | |
RU2559320C2 (ru) | Новые аналоги глюкагона | |
US20090170762A1 (en) | Treatment of Diabetes Related Obesity | |
US20090286722A1 (en) | Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function | |
KR20150003910A (ko) | Gip-glp-1 이원 작용제 화합물 및 방법 | |
KR20110043686A (ko) | 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 유사체 | |
JP2011506428A (ja) | グルカゴンアンタゴニスト活性及びglp−1アゴニスト活性を有するペプチド模倣体 | |
KR20110043688A (ko) | 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드 유사체 | |
JP2023544959A (ja) | 改善されたアミリン受容体(hAMY3R)効力を有するhAM15-52類似体 | |
WO2024003359A1 (fr) | Agonistes du récepteur de l'amyline (hamy3r) présentant une stabilité chimique améliorée |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |